Predict your next investment

Emboline company logo
HEALTHCARE | Medical Devices & Equipment / Surgical Devices
emboline.com

See what CB Insights has to offer

Founded Year

2011

Stage

Series D | Alive

Total Raised

$81.56M

Last Raised

$55M | 6 mos ago

About Emboline

Emboline is a medical device company that has developed the Emboliner Embolic Protection Catheter, an embolic protection technology for TAVR and other interventional procedures with embolic risks. The novel Emboliner device is intended to more reliably protect the cerebral system, while also capturing non-cerebral debris.

Emboline Headquarter Location

849C Almar Avenue #278

Santa Cruz, California, 95060,

United States

831-900-5020

Latest Emboline News

Emboline Raises over $55 Million in Series D Funding for Pivotal FDA Clinical Study and Market Launch of the Emboliner™ Embolic Protection Catheter to Minimize Stroke Risk from TAVR

May 26, 2021

Emboline Raises over $55 Million in Series D Funding for Pivotal FDA Clinical Study and Market Launch of the Emboliner™ Embolic Protection Catheter to Minimize Stroke Risk from TAVR Financing led by Matrix Capital Management with significant investment from an undisclosed strategic investor -- Eric Xiao of Matrix Capital Management to join the Emboline Board of Directors SANTA CRUZ, Calif., May 25, 2021-- Emboline, Inc., a privately held medical device company focused on reducing stroke and other damage caused by embolic debris released during transcatheter heart procedures, today announced the closing of its Series D funding of over $55 million. This funding was led by new investors Matrix Capital Management and an undisclosed strategic investor, with additional participation by existing investors, including SV Tech, ShangBay Capital, and Global Assets Investment. In conjunction with the financing, Eric Xiao, Principal at Matrix Capital Management along with a representative for the strategic investor have joined the Emboline Board of Directors. This investment will support a planned US-based pivotal trial for FDA approval as well as investigational studies for new indications, and manufacturing and commercial operations for the Emboliner. SVB Leerink acted as placement agent for the Company. Transcatheter aortic valve replacement (TAVR) is a lower-risk alternative to open-heart surgery, but debris (emboli) released into the bloodstream during transcatheter heart procedures can cause stroke, cognitive decline and other organ damage in patients. The Emboliner uses a unique cylindrical nitinol mesh filter that is deployed through an existing femoral artery access site and conforms to the aortic arch to capture and remove embolic debris released into the bloodstream during TAVR and other transcatheter heart procedures. A central expanding port in the filter enables passage of all procedure-related devices while maintaining complete embolic protection throughout the entire procedure. The Emboliner provides embolic debris protection for all three major cerebral aortic arch vessels as well the kidneys, abdomen and lower body. Unlike partial embolic protection or deflection devices, the Emboliner is designed to capture and remove all debris generated during transcatheter heart procedures. Results from the previous SafePass 2 clinical study, presented at TCT Connect 2020, provided the initial evidence of the safety and effectiveness of the Emboliner. In addition, the Emboliner captured and removed over 5 times the debris of the leading commercial TAVR embolic protection device, suggesting the advantages of capturing and removing all embolic debris from such interventional procedures. Eric Xiao, Principal at Matrix Capital Management said, "The mounting evidence in interventional cardiology demonstrates a clear need for embolic protection in TAVR and other transcatheter-based heart procedures, and Emboline represents best-in-class technology to address these needs. We are excited to support Emboline in bringing highly effective healthcare solutions to patients worldwide." Scott Russell, President & CEO of Emboline added, "We are excited to have Matrix Capital Management and a major strategic investor join our investor group, and are grateful for the continued support from our existing investors. These additional funds allow us to build on the successful clinical results from our previous SafePass studies, and effectively position Emboline to achieve our clinical and commercial goals and bring the best-in-class Emboliner technology to patients worldwide." About Emboline Emboline, Inc., is a privately held medical technology company that has developed the Emboliner™ total embolic protection catheter, the first embolic protection device designed to provide total embolic protection by capturing and removing all debris from transcatheter procedures that would otherwise travel to the brain, kidneys and other critical organs, and reducing the incidence of stroke, cerebral ischemia, cognitive decline and other adverse outcomes associated with procedure-related emboli. Emboline was founded by Amir Belson, MD, who is also the founder of NeoGuide Systems, Vascular Pathways, ZipLine Medical, Radiaction and others. More information is available at www.emboline.com. The Emboliner™ is not yet commercially available and is intended for investigational use only. Performance specifications and claims are subject to revision pending completion of regulatory approvals. Emboline, Emboliner and SafePass are trademarks of Emboline, Inc. Media Contact for Emboline: media@emboline.com

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Emboline

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Emboline is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Emboline Patents

Emboline has filed 24 patents.

The 3 most popular patent topics include:

  • Cardiac surgery
  • Vascular diseases
  • Interventional cardiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/26/2018

7/6/2021

Vascular diseases, Cardiac surgery, Cardiac anatomy, Interventional cardiology, Interventional radiology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/26/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/6/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Vascular diseases, Cardiac surgery, Cardiac anatomy, Interventional cardiology, Interventional radiology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Emboline Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Emboline Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.